– Revenue of $1,011.4 Million, GAAP Diluted EPS of $0.82, and Non-GAAP Diluted EPS of $1.06; All Met or Exceeded Guidance –

– Total Company Revenue Growth of 2.7%, or 3.1% in Constant Currency and 5.8% Organically excluding COVID-19; Against Growth of 18.4% in the Prior Year Period –

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal third quarter ended June 29, 2024.

“In our third quarter of fiscal 2024, Hologic returns to top-line reported growth and once again exceeded the high-end of our guidance for both the top and bottom-line,” said Stephen P. MacMillan, the Company’s Chairman, President and Chief Executive Officer. “Our strong fiscal quarter and year-to-date results continue to highlight the durable strength across our broad portfolio, with our Diagnostics (ex-COVID), Breast Health, and Surgical franchises delivering at or above our expectations. We are excited to finish fiscal 2024 strong as we continue to build for the long term.”

Recent Highlights

• Revenue of $1,011.4 million increased 2.7% for the quarter, or 3.1% in constant currency, primarily driven by higher sales in Molecular Diagnostics, Breast Imaging, and Surgical.
  • Excluding COVID-19 revenues, total organic revenue grew 5.5%, or 5.8% on a constant currency basis.
• Diagnostics revenue increased 0.3%, or 0.7% in constant currency, primarily driven by higher Molecular Diagnostics sales, partially offset by lower sales of COVID-19 assays compared to the prior year period.
  • Excluding COVID-19 revenues, Diagnostics revenue grew 6.0% on an organic, constant currency basis.
  • Molecular Diagnostics revenue grew 2.8%, or 3.1% in constant currency, primarily driven by higher sales of BV CV/TV and non-COVID-19 respiratory assays compared to the prior year period.
  • Excluding COVID-19 revenues, Molecular Diagnostics revenue grew 10.5% on an organic, constant currency basis.
• Breast Health revenue increased 6.9%, or 7.1% in constant currency, primarily driven by strong gantry sales and service.
  • Excluding SSI, Breast Health revenue increased 7.9%, or 8.2% in constant currency.
• Surgical revenue grew 5.9%, or 6.2% in constant currency, primarily driven by solid sales of MyoSure and Fluent Fluid Management products.
• Cash flow from operations remained strong in the third quarter at $405.7 million.
• Repurchased 1.4 million shares for $100 million.
• Closed the acquisition of Endomagnetics on July 25, 2024, which develops and sells breast surgery localization and lymphatic tracing technologies.

Key financial results for the fiscal third quarter shown in the table below: